News Archives - Page 9 of 11 - Buhlmann Diagnostics Corp

Category: News

Come Visit BUHLMANN at AMLI 2017- Booth #13

     AMLI 2017 BUHLMANN Diagnostics Corp  Booth: #13 August 13 - 16, 2017 Renaissance Stapleton Hotel | Denver, C0 LEARN MORE Click & Contact our AMLI 2017BUHLMANN Team Connect with our team ahead of time, learn more about the BÜHLMANN's Products and Solutions or schedule a meeting! Jennifer Stuart, Technical Sales Specialist JENNIFER STUART Technical Sales Specialist jls@buhlmannlabs.com
Continue Reading

Turbo Charged from the Start: Introducing in-house Calprotectin Testing Directly on the Roche cobas® c702

Rosie Forster, Queen Elizabeth Hospital Birmingham, with the CALEX and Roche cobas c702 BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Rosie Forster and Karen Smith, Clinical Biochemistry, Queen Elizabeth Hospital Birmingham introduce Faecal Calprotectin testing into their laboratory using the BÜHLMANN
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at Laborgemeinschaft 1 in Zurich

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version Interview with Carmela Gugliotta, Laborgemeinschaft 1, Zurich Mrs. Gugliotta, several months ago you decided to implement the BÜHLMANN fCAL® turbo on your Roche cobas® c501 system. Can you tell me why? Our customers asked
Continue Reading

Visit BUHLMANN Diagnostics Corp at AACC 2017

  AACC 2017 BUHLMANN Diagnostics Corp  Booth: #1620 July 30 – August 3 2017, 2017 San Diego Convention Center | San Diego, CA     LEARN MORE Click & Contact AACC 2017 BUHLMANN Team Connect with our team ahead of time, learn more about the BÜHLMANN's Products and Solutions or schedule a meeting! Collin Shaw, VP of Business Development
Continue Reading

Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111

BÜHLMANN fCAL® turbo: Mandic-Havelka, A. Nilsen, T. et. al. Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111.  Clin Lab.  2017 May 1;63(5):907-913. doi: 10.7754/Clin.Lab.2016.161032.  PMID: 28627817 Highlights from this Publication “The assay was linear in the range between 20 and 1,900 µg/g with a limit of quantification around 20
Continue Reading

BUHLMANN LabSense News: Spring 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the third edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News.  Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition,
Continue Reading

Visit BUHLMANN at DDW 2017- Booth 1925

Digestive Diseases Week (DDW) 2017 BUHLMANN Diagnostics Corp  Booth: #1925 May 06 - 09, 2017 | McCormick Place | Chicago, IL Learn More Click & Contact DDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! Collin Shaw, VP of Business Development Jennifer Stuart, Technical
Continue Reading

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class 2 medical devices
Continue Reading

BUHLMANN Highlights: GanglioCombi MAG ELISA

BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100476 DOWNLOAD WHITE PAPER BÜHLMANN GanglioCombi® MAG ELISA Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b). The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric
Continue Reading

The Value of Calprotectin in Inflammatory Bowel Disease Management

Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as  can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading